Overview

Nerandomilast, marketed as Jascayd, approaches pulmonary fibrosis from a signaling perspective rather than an immune-suppression one. The compound selectively inhibits phosphodiesterase 4B (PDE4B), an enzyme highly expressed in lung tissue that breaks down cyclic adenosine monophosphate (cAMP). By preserving cAMP inside alveolar cells, the drug shifts the intracellular balance away from pathways that drive fibroblast activation, collagen deposition, and inflammatory cytokine release. The 18mg tablet strength is supplied for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), and understanding this mechanism helps procurement teams explain to clinicians why the molecule differs from earlier antifibrotic agents.

The cAMP Degradation Problem in Fibrotic Lung Tissue

PDE4B is one of the dominant phosphodiesterase isoforms in the human lung. Its normal job is to hydrolyze cAMP, keeping the second messenger within a controlled range. In fibrotic disease, this activity becomes problematic: reduced cAMP signaling removes a natural brake on fibroblast-to-myofibroblast transformation and on the release of pro-inflammatory mediators such as TNF-alpha and IL-1 beta. When nerandomilast blocks PDE4B, cAMP concentrations rise inside affected cells. Elevated cAMP, in turn, suppresses cytokine production and dampens the activation signals that transform resting fibroblasts into collagen-secreting myofibroblasts. This is a direct intervention in the fibrotic cascade rather than broad immunosuppression, which is why the molecule can be studied in both IPF and the progressive fibrosing phenotype.

Dosing Flexibility and Interaction-Aware Prescribing

The approved adult dosing is 18mg taken twice daily. For patients who tolerate the regimen poorly, labeling allows a reduction to 9mg twice daily. One clinically important exception exists: when nerandomilast is co-administered with pirfenidone, exposure to nerandomilast decreases, so the reduced 9mg dose should not be used in that combination. Gastrointestinal effects such as diarrhea and weight loss are among the commonly reported adverse reactions, which is a practical consideration when hospitals plan patient counseling around this molecule. Regulatory review by both FDA and EMA drew on phase 3 data showing a slowing of lung function decline in IPF patients, and the indication was subsequently extended to progressive pulmonary fibrosis.

FAQ

Q: What enzyme does nerandomilast target inside the lung?

A: It selectively inhibits phosphodiesterase 4B, the enzyme responsible for degrading cAMP in alveolar tissue, thereby keeping this second messenger at levels that restrain fibroblast activation.

Q: Can the 18mg twice-daily regimen be lowered if side effects appear?

A: Yes, labeling permits a reduction to 9mg twice daily, except when pirfenidone is given concurrently, because pirfenidone lowers nerandomilast exposure and the reduced strength is not recommended in that pairing.

Q: Which patient populations is Jascayd indicated for?

A: The product is supplied for adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, two conditions characterized by advancing scarring of lung tissue.